Efficacy and safety of neoadjuvant immunotherapy combined with chemotherapy for resectable non-small cell lung cancer
- VernacularTitle:新辅助免疫治疗联合化疗在可切除非小细胞肺癌中的疗效与安全性分析
- Author:
Dongbao YANG
1
;
Kaize ZHONG
2
;
Hongmei MA
2
;
Shifa ZHANG
2
;
Hongfeng LIU
2
;
Liji CHEN
1
;
Jishen ZHANG
1
;
Haibo CAI
2
Author Information
1. Jining Medical University, Jining, 272000, Shandong, P. R. China
2. Department of Thoracic Surgery, The First People's Hospital of Jining, Jining, 272000, Shandong, P. R. China
- Publication Type:Journal Article
- Keywords:
Non-small cell lung cancer;
neoadjuvant therapy;
immunotherapy;
chemotherapy;
pathological reaction;
surgery
- From:
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery
2026;33(06):920-926
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the efficacy and safety of neoadjuvant immunotherapy combined with chemotherapy in patients with locally advanced resectable non-small cell lung cancer (NSCLC). Methods The clinical data of patients with stage ⅡA-ⅢB NSCLC who underwent surgical treatment after receiving neoadjuvant immunotherapy combined with chemotherapy or chemotherapy alone at the First People’s Hospital of Jining between April 2021 and January 2024 were retrospectively analyzed. According to the preoperative neoadjuvant regimens, the patients were divided into a combined group and a chemotherapy group, and the clinical data of the two groups were compared. Results A total of 66 patients were included, including 61 males and 5 females. There were 53 patients in the combined group with a mean age of (63.40±6.80) years, and 13 patients in the chemotherapy group with a mean age of (58.62±8.30) years. There was a statistical difference in age between the two groups (P＜0.001), while no statistical difference was observed in other baseline data (P>0.05). The major pathological response rates in the combined group and the chemotherapy group were 54.7% and 23.1%, respectively (P=0.041), and the pathological complete response rates were 39.6% and 0.0%, respectively (P=0.006). The operative time in the combined group was shorter (P=0.039). There were no statistical differences between the two groups in intraoperative blood loss, duration of postoperative tube carrying, incidence of postoperative complications, overall survival, or event-free survival (P>0.05). Conclusion Surgical treatment following neoadjuvant immunotherapy combined with chemotherapy is safe and feasible, and its long-term efficacy requires further follow-up for confirmation.
